Gallagher Tara, Taliercio Mark, Nia John K, Hashim Peter W, Zeichner Joshua A
Ms. Gallagher is with the University of Notre Dame in Notre Dame, Indiana.
Mr. Taliercio and Drs. Nia, Hashim, and Zeichner are with Mount Sinai Hospital in New York, New York.
J Clin Aesthet Dermatol. 2020 Dec;13(12):41-43. Epub 2020 Dec 1.
Despite common administration of intralesional triamcinolone to acne lesions, there is little published data or consensus on best practices. This study aimed to evaluate specific characteristics of intralesional triamcinolone for acne among various dermatology healthcare professionals. One hundred participants (82 attending physicians, 9 physician assistants, 8 other healthcare professionals, and 1 unidentified) from private practices and academic centers completed a 10-question survey to assess specific characteristics of intralesional triamcinolone injections, including frequency, indication, depth of injection, concentration, volume, as development of adverse events. The most common reported concentration of intralesional triamcinolone was 2.5mg/mL (52.5%). The most frequently used volume injected was 0.05mL (42.3%). In total, 61.6 percent of those surveyed answered that they inject into the center of the lesion. Additionally, 50.5 percent of respondents counsel patients on potential adverse effects of hypopigmentation and atrophy before every injection. The majority of respondents (88.8%) reported that less than one percent of their patients returned for adverse events resulting from triamcinolone usage, and 48.4 percent reported that atrophy lasted over six months (48.4%). The data collected from this study can offer guidance on best practices in administering intralesional kenalog to patients. While consistency exists for the concentration of triamcinolone used, there was significant discordance in the volumes and depth of triamcinolone injection. Observed skin atrophy rates are extremely low, but they are long lasting when it occurred. We can use these data to refine our treatment techniques as well as improve treatment outcomes and patient satisfaction.
尽管在痤疮皮损内注射曲安奈德很常见，但关于最佳实践的已发表数据和共识却很少。本研究旨在评估不同皮肤科医护人员在痤疮皮损内注射曲安奈德的具体特征。来自私人诊所和学术中心的100名参与者（82名主治医师、9名医师助理、8名其他医护人员和1名身份不明者）完成了一项包含10个问题的调查，以评估皮损内注射曲安奈德的具体特征，包括频率、适应证、注射深度、浓度、剂量以及不良事件的发生情况。报告的皮损内曲安奈德最常见浓度为2.5mg/mL（52.5%）。最常用的注射剂量为0.05mL（42.3%）。总体而言，61.6%的受访者表示他们将药物注射到皮损中心。此外，50.5%的受访者在每次注射前都会告知患者色素减退和萎缩等潜在不良反应。大多数受访者（88.8%）报告称，因使用曲安奈德导致不良事件而返回的患者不到1%，48.4%的受访者报告称萎缩持续超过6个月（48.4%）。本研究收集的数据可为向患者注射皮损内康宁克通的最佳实践提供指导。虽然使用的曲安奈德浓度存在一致性，但在曲安奈德的注射剂量和深度方面存在显著差异。观察到的皮肤萎缩发生率极低，但一旦发生，持续时间很长。我们可以利用这些数据来改进我们的治疗技术，以及改善治疗效果和患者满意度。
